Panelists discuss how the MARIPOSA study findings demonstrated significant progression-free survival and overall survival ...

Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated ...

Panelists discuss how both amivantamab plus lazertinib and osimertinib-based regimens show good central nervous system (CNS) ...

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, ...

In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.

Formal communication could help ease the transition of care from specialized myeloma centers to community clinic, according ...

Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma.

Oncology nurses can help patients understand this novel mechanism of action and its potential as a treatment option.

The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer ...

Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at ...

Q&A: Prioritizing QOL Important to Treating HR+, HER2- Metastatic Breast Cancer ...

Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane ...